Biologics Development Strategies

Home / Biologics Development Strategies

Biologics Development Strategies

Expertise and Services

Atebion’s combination of technical and commercial expertise will ensure that our partners can initiate and progress their biotherapeutic targets to clinical and commercial success

The generation of regulatory compliant, core assets associated with the development of biotherapeutics, alongside development of robust, reproducible biological production processes, is the cornerstone of successful progression of any pre-clinical and clinical strategy

Through its expertise and associated partners, Atebion BDS can provide supporting services to develop regulatory compliant, cost effective, technical development strategies relating to the manufacturing of multiple product classes from a broad range of production methods. Atebion BDS has broad expertise in mammalian, microbial and viral based production including the development of novel targets, biosimilars and emerging drug classes such as Antibody Drug Conjugates.

This background, encompassing all aspects from early stage molecular biology & cell line development through to clinical manufacturing – including the development of a range of drug delivery devices – enables us to fully support our partners’ technical requirements. Through our commercial expertise, we are also able advise, guide or lead the successful development, partnering, licensing and/ or marketing of these high value biotherapeutics.

Our services include:

Proposition development and technical/commercial based diligence for investment and licensing

  • Provision of technical and commercial strategies for process development, technical transfer and manufacturing drug substance and drug product
  • Managing interactions between CMC, pre-clinical/clinical, regulatory and marketing functions
  • Support in identifying and negotiating contractual agreements with Contract Development and Manufacturing/Research Organisations and associated 3rd party partners
  • Developing financial models including 3rd part licenses required for biotherapeutic development


What Our Clients Say